Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QTc Prolongation Liability Determinations: A Pharma Perspective

Vargas, Hugo M and Rolf, Mike and Wisialowski, Todd A and Anchazar, William and Bahinski, Anthony and Bass, Alan and Benson, Charles and Chaudry, Khuram W and Couvreur, Nicolas and Dota, Carina and Mike, Engwall and Gallacher, David and Greiter-Wilke, Andrea and Guillon, Jean-Michel and Guth, Brian and Herbert, Himmel and Ito, Maki and Jenkinson, Stephen and Katsuyoshi, Chiba and Kochihoro, Ogata and Taeko, Kubo and Armando, Lagrutta and Paul, Levesque and Eric, Martel and Yoshiko, Okai and Ravi, Peri and Ami, Pointon and Yusheng, Qu and Teisman, Ard and Traebert, Martin and Takashi, Yoshinaga and Gary, Gintant and Derek, Leishman and Derek, Valentin (2020) Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QTc Prolongation Liability Determinations: A Pharma Perspective. Clinical Pharmacology & Therapeutics. ISSN 0009-92361532-6535

Abstract

The appropriate and efficient assessment of drug-induced clinical QTc prolongation (a surrogate marker of Torsades de Pointes arrhythmia) remains a concern of drug developers and regulators worldwide. Refined and validated over 15+ years, the nonclinical ICH S7B guidance describes two core assays (in vitro hERG/IKr current & in vivo QT studies) to assess the potential for delayed ventricular repolarization. Incorporating these assays early in candidate selection has lead to: i) a low prevalence of QTc prolonging drugs in clinical trials, and ii) no drugs have been removed from the marketplace due to unexpected QTc prolongation. Despite this success, nonclinical findings still minimally influence ICH E14-based strategies for interpreting clinical QTc prolongation, and defining proarrhythmic risk.
In particular, the value of ICH S7B-based findings for candidates demonstrating minimal hERG/IKr block and minimal in vivo QTc prolongation at comparable clinical exposures (i.e., “double-negative nonclinical findings” are underestimated. Such reassuring nonclinical data has clear value assessing the risk of clinical QTc prolongation when clinical evaluation may be challenged by heart rate changes, exposure limitations, or safety considerations.
The time has come to meaningfully merge nonclinical and clinical approaches to provide a more comprehensive and integrated proarrhythmia risk assessment strategy that complements advances described in ICH E14 amendments to enable more flexible clinical QTc risk assessments. Adoption of a truly integrative nonclinical/clinical risk assessment in the context of the low prevalence of QTc prolonging drugs would positively impact regulatory science, relieve the burden of extensive QTc monitoring, and streamline drug development.

Item Type: Article
Date Deposited: 20 Oct 2020 00:45
Last Modified: 20 Oct 2020 00:45
URI: https://oak.novartis.com/id/eprint/42626

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.